Cost and healthcare resource utilization (HCRU) for patients receiving neoadjuvant therapy for early-stage triple-negative breast cancer (ESTNBC)

The available economic evidence base for ESTNBC is limited. This study evaluated costs and HCRU for patients receiving neoadjuvant treatment for ESTNBC. This was a retrospective observational study of patients with ESTNBC from US community oncology practices. The results of the present study demonstrate the economic and resource burden of ESTNBC, particularly during the time from neoadjuvant treatment initiation until surgery.

Read More